The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways

No abstract is available for this paper.

• Publication year

  2008

• Venue

  JBIC Journal of Biological Inorganic Chemistry

• Publication date

  2008-07-03

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00775-008-0400-9PMID 18597125
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Spliceosomal protein E regulates neoplastic cell growth by modulating expression of Cyclin E/CDK2 and G2/M checkpoint proteins

  2008cited by this paper
• Antitumour metal compounds: more than theme and variations.

  2008cited by this paper
• Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.

  2007cited by this paper
• Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.

  2006cited by this paper
• Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds

  2006cited by this paper
• Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

  2006cited by this paper
• Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP.

  2006cited by this paper
• A Calmodulin-Binding Site on Cyclin E Mediates Ca2+-Sensitive G1/S Transitions in Vascular Smooth Muscle Cells

  2006cited by this paper
• Metal-based antitumour drugs in the post genomic era.

  2006cited by this paper
• Mechanisms of cytochrome c release from mitochondria

  2006cited by this paper
• From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

  2006cited by this paper
• Platinum group metallodrug‐protein binding studies by capillary electrophoresis – inductively coupled plasma‐mass spectrometry: A further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins

  2006cited by this paper
• Ruthenium (II)-Derived Organometallic Compounds Induce Cytostatic and Cytotoxic Effects on Mammalian Cancer Cell Lines through p53-Dependent and p53-Independent Mechanisms

  2005cited by this paper
• Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175

  2005cited by this paper
• Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human prostate cancer cells.

  2005cited by this paper
• C/EBPbeta-2 confers EGF-independent growth and disrupts the normal acinar architecture of human mammary epithelial cells

  2005cited by this paper
• Role of JNK activation in apoptosis: A double-edged sword

  2005cited by this paper
• Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential.

  2005cited by this paper
• Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats

  2005cited by this paper
• Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells

  2005cited by this paper
• In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.

  2005cited by this paper
• Enabling Death by the Abl Tyrosine Kinase: Mechanisms for Nuclear Shuttling of c-Abl in Response to DNA Damage

  2005cited by this paper
• The p53 pathway: positive and negative feedback loops

  2005cited by this paper
• Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins

  2005cited by this paper
• Binding of Organometallic Ruthenium(II) and Osmium(II) Complexes to an Oligonucleotide: A Combined Mass Spectrometric and Theoretical Study

  2005cited by this paper
• Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer.

  2004cited by this paper
• A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

  2004cited by this paper
• Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy

  2004cited by this paper
• A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins.

  2004cited by this paper
• Survivin and p53 Modulate Quercetin-induced Cell Growth Inhibition and Apoptosis in Human Lung Carcinoma Cells*

  2004cited by this paper
• New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?

  2003cited by this paper
• Regulation of Bax translocation through phosphorylation at Ser-70 of Bcl-2 by MAP kinase in NO-induced neuronal apoptosis.

  2003cited by this paper
• Long-patch base excision repair of apurinic/apyrimidinic site DNA is decreased in mouse embryonic fibroblast cell lines treated with plumbagin: involvement of cyclin-dependent kinase inhibitor p21Waf-1/Cip-1

  2002cited by this paper
• Prodigiosin Induces Caspase‐9 and Caspase‐8 Activation and Cytochrome C Release in Jurkat T Cells

  2002cited by this paper
• In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

  2002cited by this paper
• Senescence-like changes induced by expression of p21Waf1/Cip1 in NIH3T3 cell line

  2002cited by this paper
• [Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo- [3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells

  2001cited by this paper
• Cellular effects of transferrin coordinated to [Cl(NH3)5Ru]Cl2 and cis-[Cl2(NH3)4Ru]Cl

  2001cited by this paper
• Regulation of the G2/M transition by p53

  2001cited by this paper
• Cellular effects of transferrin coordinated to.

  2001cited by this paper
• TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b

  2001cited by this paper
• The biochemistry of apoptosis

  2000cited by this paper
• Ruthenium-based compounds and tumour growth control (review).

  2000cited by this paper
• Current status of platinum-based antitumor drugs.

  1999cited by this paper
• JNK targets p53 ubiquitination and degradation in nonstressed cells.

  1998cited by this paper
• Effects of Hypoxia and Transferrin on Toxicity and DNA Binding of Ruthenium Antitumor Agents in Hela Cells

  1996cited by this paper
• Is there life after technetium: what is the potential for developing new broad-based radionuclides?

  1996cited by this paper
• The binding properties of two antitumor ruthenium(III) complexes to apotransferrin.

  1994cited by this paper
• Antitumor activity of some ruthenium derivatives in human colon cancer cell lines in vitro.

  1992cited by this paper
• Interaction of tetra-azaphenanthrene ruthenium complexes with DNA and oligonucleotides. A photophysical and photochemical investigation.

  1990cited by this paper
• A new cholescintigraphic agent: ruthenium-97-DISIDA.

  1989cited by this paper
• Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats.

  1989cited by this paper
• The mechanism of action of platinum antitumor drugs

  1987cited by this paper
• Reaction of cis-RuII(DMSO)4Cl2 with DNA and with some of its bases in aqueous solution

  1987cited by this paper

• Reactivity of [(arene)(chloro)(phosphino)ruthenium(II)]+ complexes towards thiourea nucleophiles

  2025cites this paper
• Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy for BRCA1-Associated Triple-Negative Breast Cancer

  2025cites this paper
• Bilosomal Encapsulation of Binuclear Phosphino Ru(II)–Cu(II) Compounds Enhances Their Selectivity and Activity toward Lung and Prostate Cancers

  2025cites this paper
• Combinative Treatment of the PARP Inhibitor Olaparib and Antimetastasis Ruthenium(II)–Arene Compound RAPTA-T for Triple-Negative BRCA1 Wild-Type Breast Cancer Cells

  2025cites this paper
• Influence of the charge of 1,3,5-triaza-7-phosphaadamantane-based ligands on the anticancer activity of organopalladium complexes

  2025cites this paper
• Ruthenium-Based Anticancer Agents: Focus on Mononuclear Ru(II)–Arene Organometallic Scaffolds and Ru(III) Non-Arene Coordination Compounds as Clinical Leads

  2025cites this paper
• Exploring photophysical, photochemical, and photobiological dynamics of binuclear transition metal complexes

  2025cites this paper
• Biological Applications, In Vitro Cytotoxicity, Cellular Uptake, and Apoptotic Pathway Studies Induced by Ternary Cu (II) Complexes Involving Triflupromazine with Biorelevant Ligands

  2024cites this paper
• Revolutionizing anticancer treatment: Ruthenium-based nanoplatforms pave new paths

  2024cites this paper
• Tumor-targeted glutathione oxidation catalysis with ruthenium nanoreactors against hypoxic osteosarcoma

  2024cites this paper
• Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides—Current Developments in Structure-Activity Relationship

  2024cites this paper
• Analysis of antiproliferative activity of new half-sandwich arene Ru(II) thiophene based aroylhydrazone complexes.

  2024cites this paper
• RAPTA-coordinated polydiacetylene self-assembly: A chameleon-like prodrug with a dual-lock strategy for real-time release monitoring of metallodrug.

  2024cites this paper
• Design of an anticancer organoruthenium complex as the guest and polydiacetylene-coated fluorogenic nanocarrier as the host: engineering nanocarrier using ene-yne conjugation for sustained guest release, enhanced anticancer activity and reduced in vivo toxicity.

  2023cites this paper
• Metalofármacos à Base de Rutênio: Uma Busca por Complexos Metálicos Bioativos de Baixa Toxicidade

  2023cites this paper
• NRF2 and Bip Interconnection Mediates Resistance to the Organometallic Ruthenium-Cymene Bisdemethoxycurcumin Complex Cytotoxicity in Colon Cancer Cells

  2023cites this paper
• Molecular studies regarding colon cancer cell line (HCT116) treated by new ruthenium and palladium complexes

  2023cites this paper
• Synthesis of Novel N-Heterocyclic Carbene-Ruthenium (II) Complexes, “Precious” Tools with Antibacterial, Anticancer and Antioxidant Properties

  2023cites this paper
• An overview of advancement of organoruthenium(II) complexes as prospective anticancer agents

  2023cites this paper
• Rh(III) and Ru(II) complexes with phosphanyl-alkylamines: inhibition of DNA synthesis induced by anticancer Rh complex.

  2023cites this paper
• Ionic mononuclear [Fe] and heterodinuclear [Fe,Ru] bis(diphenylphosphino)alkane complexes: Synthesis, spectroscopy, DFT structures, cytotoxicity, and biomolecular interactions.

  2023cites this paper
• A comprehensive review on metallodrugs in breast cancer treatment

  2023cites this paper
• Metal Complexes in Cancer Treatment: Journey So Far

  2023cites this paper
• Dichloro Ru(II)-p-cymene-1,3,5-triaza-7-phosphaadamantane (RAPTA-C): A Case Study.

  2023cites this paper
• Insights into the κ-P,N Coordination of 1,3,5-Triaza-7-phosphaadamantane and Derivatives: κ-P,N-Heterometallic Complexes and a 15N Nuclear Magnetic Resonance Survey

  2022cites this paper
• A split β-lactamase sensor for the detection of DNA modification by cisplatin and ruthenium-based chemotherapeutic drugs.

  2022cites this paper
• Promising anticancer activity with high selectivity of DNA/plasma protein targeting new phthalazin-1(2H)-one heterocyclic scaffolds

  2022cites this paper
• Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy.

  2022cites this paper
• Construction of homo and heteronuclear Ru(II), Ir(III) and Re(I) complexes for target specific cancer therapy

  2022cites this paper
• Competitive binding studies of the nucleosomal histone targeting drug, [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C), with oligonucleotide-peptide mixtures.

  2022cites this paper
• Experimental and Theoretical Analysis of Metal Complex Diffusion through Cell Monolayer

  2021cites this paper
• Trans-palladium complexes with 1-adamantanamine and various halide ions: Synthesis, characterization, DNA and protein binding and in vitro cytotoxicity

  2021cites this paper
• Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma

  2021influential citation
• Ruthenium(ii)-arene complexes as anti-metastatic agents, and related techniques.

  2021cites this paper
• Critical factors affecting the albumin binding of half-sandwich Ru(II) and Rh(III) complexes of 8-hydroxyquinolines and oligopyridines.

  2021cites this paper
• First 97Ru complex with pyridine-2,6-dicarboxamide conjugate for potential use as radiopharmaceutical

  2021cites this paper
• Half-sandwich ruthenium (II) p-cymene complexes based on organophosphorus ligands: Structure determination, computational investigation, in vitro antiproliferative effect in breast cancer cells and antimicrobial activity

  2021cites this paper
• Investigation of the Effects and Mechanisms of Anticancer Action of a Ru(II)‐Arene Iminophosphorane Compound in Triple Negative Breast Cancer Cells

  2021cites this paper
• Assessment of antiproliferative activity of new half‐sandwich arene Ru (II) furylbenzhydrazone complexes

  2021cites this paper
• Imidazole/4,4′-azopyridine bridging binuclear Ru(II) complexes: design, synthesis, bimolecular interactions and cytotoxicity against HeLa cell line

  2021cites this paper
• Ruthenium Complexes as Promising Candidates against Lung Cancer

  2021cites this paper
• Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib

  2021cites this paper
• Tridentate 3-Substituted Naphthoquinone Ruthenium Arene Complexes: Synthesis, Characterization, Aqueous Behavior, and Theoretical and Biological Studies

  2021cites this paper
• Metallodrugs are unique: opportunities and challenges of discovery and development

  2020cites this paper
• A review on homo multinuclear anticancer Metallotherapuetics

  2020cites this paper
• Facile entry to germanate and stannate complexes [(η6-arene)RuCl(η2-dppm)]+[ECl3]- (E = Ge, Sn) as potent anti-cancer agents

  2020cites this paper
• Recent advances in cytotoxicity, cellular uptake and mechanism of action of ruthenium metallodrugs: A review

  2020cites this paper
• Spectral and molecular docking studies of nucleic acids/protein binding interactions of a novel organometallic palladium (II) complex containing bioactive PTA ligands: Its synthesis, anticancer effects and encapsulation in albumin nanoparticles

  2020cites this paper
• Modulation of Amyloidogenic Peptide Aggregation by Photoactivatable CO-Releasing Ruthenium(II) Complexes

  2020cites this paper
• Mitochondria-Targeting Click-Derived Pyridinyltriazolylmethylquinoxaline-Based Y-Shaped Binuclear Luminescent Ruthenium(II) and Iridium(III) Complexes as Cancer Theranostic Agents.

  2020cites this paper
• A review on 1,1-bis(diphenylphosphino)methane bridged homo- and heterobimetallic complexes for anticancer applications: Synthesis, structure, and cytotoxicity.

  2020cites this paper
• DFT based computational methodology of IC50 prediction.

  2020cites this paper
• (η6-Arene) ruthenium(II) complexes with ferrocene-tethered salicylaldimine ligands: Synthesis, characterization and anti-cancer properties

  2020cites this paper
• Synthesis and Structure of Arene Ru(II) N∧O-Chelating Complexes: In Vitro Cytotoxicity and Cancer Cell Death Mechanism

  2020cites this paper
• Fluorinated-NHC Transition Metal Complexes Leading Characters as Potential Anticancer Metallodrugs.

  2020cites this paper
• The rate of substitution from η6-arene ruthenium(II) complexes

  2020cites this paper
• Synthesis, characterization, photodynamic activity of half-sandwich rhodium(III) complexes with curcuminoids.

  2020cites this paper
• Biomedical Applications of Metal Organic Polygons and Polyhedra (MOPs).

  2020cites this paper
• Antitumor Activity of Pt(II), Ru(III) and Cu(II) Complexes

  2020cites this paper
• Metalloproteomics for molecular target identification of protein-binding anticancer metallodrugs.

  2020cites this paper
• Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity

  2019cites this paper
• Heterobimetallic Ru(μ-dppm)Fe and homobimetallic Ru(μ-dppm)Ru complexes as potential anti-cancer agents

  2019cites this paper
• Estudo das vias de sinalização envolvidas na apoptose induzida pelo complexo de rutênio com timina em células de carcinoma de cólon humano HCT116

  2019cites this paper
• Ru(II)-thymine complex causes DNA damage and apoptotic cell death in human colon carcinoma HCT116 cells mediated by JNK/p38/ERK1/2 via a p53-independent signaling

  2019cites this paper
• Recent advances in ruthenium and platinum based supramolecular coordination complexes for antitumor therapy.

  2019cites this paper
• Antitumor activity of organoruthenium complexes with chelate aromatic ligands, derived from 1,10-phenantroline: Synthesis and biological activity.

  2019cites this paper
• Binding mechanisms of half-sandwich Rh(III) and Ru(II) arene complexes on human serum albumin: a comparative study

  2019cites this paper
• The cytotoxic effect of Ru(II) complexes with 5-(2-hydroxyphenyl)-3-methyl-1-(2-pyridyl)-1H-pyrazole-4-carboxylic acid methyl ester: Synthesis, X-ray structure and DNA damage potential

  2019cites this paper
• Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T

  2019cites this paper
• Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies

  2019cites this paper
• Novel half-sandwich rhodium(III) and iridium(III) photosensitizers for dual chemo- and photodynamic therapy.

  2019cites this paper
• Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?

  2019cites this paper
• Elucidation of the Mechanism of Action for Metal Based Anticancer Drugs by Mass Spectrometry-Based Quantitative Proteomics

  2019cites this paper
• A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53.

  2019cites this paper
• Progress in the Utilisation of Organometallic Compounds in the Development of Cancer Drugs

  2019cites this paper
• Synthesis of Camphor-Derived Bis(pyrazolylpyridine) Rhodium(III) Complexes: Structure-Reactivity Relationships and Biological Activity.

  2019cites this paper
• DFT Based Computational Methodology of IC50

  2019cites this paper
• Nano-Based Systems and Biomacromolecules as Carriers for Metallodrugs in Anticancer Therapy

  2018cites this paper
• Isomeric ruthenium(II) complexes for cancer therapy and cellular imaging

  2018cites this paper
• New Ru(II) half sandwich complexes bearing the N,N′ bidentate 9-ethyl-N-(pyridin-2-ylmethylene)9H-carbazole-3-amine ligand: Effects of halogen (Cl−, Br− and I−) leaving groups versus in vitro activity on HepG2 cancer cells, cell cycle, fluorescence study, cellular accumulation and DFT study

  2018cites this paper
• Microfocus x-ray fluorescence mapping of tumour penetration by an organo‑osmium anticancer complex.

  2018cites this paper
• Organometallic ruthenium(II) complexes containing NS donor Schiff bases: Synthesis, structure, electrochemistry, DNA/BSA binding, DNA cleavage, radical scavenging and antibacterial activities

  2018cites this paper
• Synthesis, cytotoxicity and anti-metastatic properties of new pyridyl–thiazole arene ruthenium(II) complexes

  2018cites this paper
• Half-Sandwich Metal Complexes with β-Diketone-Like Ligands and Their Anticancer Activity

  2018cites this paper
• Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.

  2018cites this paper
• Half-Sandwich Ru(II) and Os(II) Bathophenanthroline Complexes Containing a Releasable Dichloroacetato Ligand

  2018cites this paper
• Bioimaging of isosteric osmium and ruthenium anticancer agents by LA-ICP-MS.

  2018cites this paper
• Synthesis, structural analysis, redox properties and in vitro antitumor evaluation of half-sandwich complexes of Ru(II) with aminocoumarins

  2017cites this paper
• Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1.

  2017cites this paper
• Arene Ruthenium(II) Complexes with Phosphorous Ligands as Possible Anticancer Agents.

  2017cites this paper
• Cytotoxicity in vitro, cellular uptake, localization and apoptotic mechanism studies induced by ruthenium(II) complex

  2017cites this paper
• The Microbiology of Ruthenium Complexes.

  2017cites this paper
• Synthesis, structure and antiproliferative activity of organometallic iridium(III) complexes containing thiosemicarbazone ligands

  2017cites this paper
• Comparative investigation of interactions between two ruthenium(II) arene PTA type complexes with curcuminoid ligands and human serum albumin

  2017cites this paper
• Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity.

  2017cites this paper
• Synthesis, characterization, cellular uptake and apoptosis-inducing properties of two highly cytotoxic cyclometalated ruthenium(II) β-carboline complexes.

  2017cites this paper
• Trends and Perspectives of Ruthenium Anticancer Compounds (Non‐PDT)

  2017cites this paper
• The effect of incorporating carboxylic acid functionalities into 2,2′-bipyridine on the biological activity of the complexes formed: synthesis, structure, DNA/protein interaction, antioxidant activity and cytotoxicity

  2017cites this paper
• Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity

  2017cites this paper
• Enhanced Antimetastatic Activity of the Ruthenium Anticancer Drug RAPTA-C Delivered in Fructose-Coated Micelles.

  2017cites this paper